Synthesis Anticonvulsant and Cytotoxic Evaluation of Benzimidazole-Quinoline Hybrids Schiff Base Analogs

Reference

• W. Loscher, “Current Status and Future Directions in the Pharmacotherapy of Epilepsy,” Trends in Pharmacological Sciences 23, no. 3 (2002): 113–8. doi:10.1016/S0165-6147(00)01974-X
   PubMed Web of Science ®Google Scholar
• N. S. Santhosh, S. Sinha, and P. Satishchandra, “Epilepsy: Indian Perspective,” Annals of Indian Academy of Neurology 17 (2014): 3–11. doi:10.4103/0972-2327.128643
   PubMed Web of Science ®Google Scholar
• K. M. Sauro, S. Wiebe, C. Dunkley, J. Janszky, E. Kumlien, S. Moshé, N. Nakasato, T. A. Pedley, E. Perucca, H. Senties, et al, “The Current State of Epilepsy Guidelines: A Systematic Review,” Epilepsia 57, no. 1 (2016): 13–23. doi:10.1111/epi.13273
   PubMed Web of Science ®Google Scholar
• Y. Gong, S. Somersan Karakaya, X. Guo, P. Zheng, B. Gold, Y. Ma, D. Little, J. Roberts, T. Warrier, X. Jiang, et al, “Benzimidazole-Based Compounds Kill Mycobacterium tuberculosis,” European Journal of Medicinal Chemistry 75 (2014): 336–53. doi:10.1016/j.ejmech.2014.01.039
   PubMed Web of Science ®Google Scholar
• N. C. Desai, G. M. Kotadiya, and A. R. Trivedi, “Studies on Molecular Properties Prediction, Antitubercular and Antimicrobial Activities of Novel Quinoline Based Pyrimidine Motifs,” Bioorganic & Medicinal Chemistry Letters 24, no. 14 (2014): 3126–30. doi:10.1016/j.bmcl.2014.05.002
   PubMed Web of Science ®Google Scholar
• A. T. Taher, N. A. Khalil, and E. M. Ahmed. “Synthesis of Novel Isatin-Thiazoline and Isatin-Benzimidazole Conjugates as anti-Breast Cancer Agents,” Archives of Pharmacal Research 34, no. 10 (2011): 1615–21. doi:10.1007/s12272-011-1005-3
   PubMed Web of Science ®Google Scholar
• S. Broch, B. Aboab, F. Anizon, and P. Moreau, “Synthesis and in Vitro Antiproliferative Activities of Quinoline Derivatives,” European Journal of Medicinal Chemistry 45, no. 4 (2010): 1657–62. doi:10.1016/j.ejmech.2010.01.003
   PubMed Web of Science ®Google Scholar
• A. Worachartcheewan, C. Nantasenamat, C. Isarankura-Na-Ayudhya, and V. Prachayasittikul, “QSAR Study of Amidino Bis-Benzimidazole Derivatives as Potent Anti-malarial Agents Against Plasmodium falciparum,” Chemical Papers 67 (2013): 1462–73. doi:10.2478/s11696-013-0398-5
   Web of Science ®Google Scholar
• Y. Q. Hu, C. Gao, S. Zhang, L. Xu, Z. Xu, L. S. Feng, X. Wu, and F. Zhao, “Quinoline Hybrids and Their Antiplasmodial and Antimalarial Activities,” European Journal of Medicinal Chemistry 139 (2017): 22–47. doi:10.1016/j.ejmech.2017.07.061
   PubMed Web of Science ®Google Scholar
• D. Seenaiah, P. R. Reddy, G. M. Reddy, A. Padmaja, V. Padmavathi, and N. S. Krishna, “Synthesis, Antimicrobial and Cytotoxic Activities of Pyrimidinyl Benzoxazole, Benzothiazole and Benzimidazole,” European Journal of Medicinal Chemistry 77 (2014): 1–7. doi:10.1016/j.ejmech.2014.02.050
   PubMed Web of Science ®Google Scholar
• S. Eswaran, A. V. Adhikari, and N. S. Shetty, “Synthesis and Antimicrobial Activities of Novel Quinoline Derivatives Carrying 1, 2, 4-Triazole Moiety,” European Journal of Medicinal Chemistry 44, no. 11 (2009): 4637–47. doi:10.1016/j.ejmech.2009.06.031
   PubMed Web of Science ®Google Scholar
• H. Küçükbay, R. Durmaz, E. Orhan, and S. Günal, “Synthesis, Antibacterial and Antifungal Activities of Electron-Rich Olefins Derived Benzimidazole Compounds Il,” Farmaco (Societa chimica italiana : 1989) 58, no. 6 (2003): 431–7. doi:10.1016/S0014-827X(03)00068-5
   PubMedGoogle Scholar
• M. F. El Shehry, M. M. Ghorab, S. Y. Abbas, E. A. Fayed, S. A. Shedid, and Y. A. Ammar, “Quinoline Derivatives Bearing Pyrazole Moiety: Synthesis and Biological Evaluation as Possible Antibacterial and Antifungal Agents,” European Journal of Medicinal Chemistry 143, no. 1 (2018): 1463–73. doi:10.1016/j.ejmech.2017.10.046
   PubMedGoogle Scholar
• P. Selvam, D. R. Lakra, and C. Pannecouque, “Synthesis, Anti-viral and Cytotoxicity Studies of Some Novel N-Substituted Benzimidazole Derivatives,” International Journal Pharmaceutical Research 1, no. 9 (2010): 105–9.
   Google Scholar
• A. Carta, I. Briguglio, S. Piras, P. Corona, G. Boatto, M. Nieddu, P. Giunchedi, M. E. Marongiu, G. Giliberti, F. Iuliano, et al, “Quinoline Tricyclic Derivatives. Design, Synthesis, and Evaluation of the Antiviral Activity of Three New Classes of RNA-Dependent RNA Polymerase Inhibitors,” Bioorganic & Medicinal Chemistry 19, no. 23 (2011): 7070–84. doi:10.1016/j.bmc.2011.10.009
   PubMed Web of Science ®Google Scholar
• K. C. S. Achar, K. M. Hosamani, and H. R. Seetharamareddy, “In-Vivo Analgesic and Anti-Inflammatory Activities of Newly Synthesized Benzimidazole Derivatives,” European Journal of Medicinal Chemistry 45, no. 5 (2010): 2048–54. doi:10.1016/j.ejmech.2010.01.029
   PubMed Web of Science ®Google Scholar
• R. V. Shingalapur, K. M. Hosamani, R. S. Keri, and M. H. Hugar, “Derivatives of Benzimidazole Pharmacophore: Synthesis, Anticonvulsant, Antidiabetic and DNA Cleavage Studies,” European Journal of Medicinal Chemistry 45, no. 5 (2010): 1753–9. doi:10.1016/j.ejmech.2010.01.007
   PubMed Web of Science ®Google Scholar
• N. Muruganantham, R. Sivakumar, N. Anbalagan, V. Gunasekaran, and J. T. Leonard, “Synthesis, Anticonvulsant and Antihypertensive Activities of 8-Substituted Quinoline Derivatives,” Biological and Pharmaceutical Bulletin 27, no. 10 (2004): 1683–7. doi:10.1248/bpb.27.1683
   PubMed Web of Science ®Google Scholar
• W. Zhu, Y. Da, D. Wu, H. Zheng, L. Zhu, L. Wang, Y. Yan, and Z. Chen, “Design, Synthesis and Biological Evaluation of New 5-Nitro Benzimidazole Derivatives as AT1 Antagonists with Anti-hypertension Activities,” Bioorganic & Medicinal Chemistry 22, no. 7 (2014): 2294–302. doi:10.1016/j.bmc.2014.02.008
   PubMed Web of Science ®Google Scholar
• D. Diaconu, V. Antoci, V. Mangalagiu, D. A. Mantu, and I. I. Mangalagiu, “Quinoline–Imidazole/Benzimidazole Derivatives as Dual-/Multi-Targeting Hybrids Inhibitors with Anticancer and Antimicrobial Activity,” Scientific Reports 12, no. 1 (2022): 16988. doi:10.1038/s41598-022-21435-6
   PubMed Web of Science ®Google Scholar
• O. F. Elebij, O. O. Ajani, G. O. Oduselu, T. A. Ogunnupebi, and E. Adebiyi, “Recent Advances in Functionalized Quinoline Scaffolds and Hybrids-Exceptional Pharmacophore in Therapeutic Medicine,” Frontiers in Chemistry 10 (2022): 1074331. doi:10.3389/fchem.2022.1074331
   PubMed Web of Science ®Google Scholar
• https://www.who.int/news-room/fact-sheets/detail/cancer (accessed July 26, 2021).
   Google Scholar
• R. A. Smith, V. Cokkinides, D. Brooks, D. Saslow, and O. W. Brawley, “Cancer Screening in the United States, 2010: A Review of Current American Cancer Society Guidelines and Issues in Cancer Screening,” CA: a Cancer Journal for Clinicians 60, no. 2 (2010): 99–119. doi:10.3322/caac.20063
   PubMed Web of Science ®Google Scholar
• https://www.ncdirindia.org/All_Reports/Report_2020/resources/NCRP_2020_2012_16.pdf
   Google Scholar
• V. Asati, D. K. Mahapatra, and S. K. Bharti, “Thiazolidine-2, 4-Diones as a Multi-Targeted Scaffold in Medicinal Chemistry: Potential Anticancer Agents,” European Journal of Medicinal Chemistry 87, no. 24 (2014): 814–33. doi:10.1016/j.ejmech.2014.10.025
   PubMedGoogle Scholar
• J. C. Reed, “Apoptosis-Based Therapies,” Nature Reviews Drug Discovery 1 (2002): 111–21. doi:10.1038/nrd726
   PubMed Web of Science ®Google Scholar
• J. C. Reed and M. Pellecchia, “Apoptosis-Based Therapies for Hematologic Malignancies,” Blood 106, no. 2 (2005): 408–18. doi:10.1182/blood-2004-07-2761
   PubMed Web of Science ®Google Scholar
• Q. P. Peterson, D. C. Hsu, D. R. Goode, C. J. Novotny, R. K. Totten, and P. J. Hergenrother, “Procaspase-3 Activation as an Anti-Cancer Strategy: Structure-Activity Relationship of Procaspase-Activating Compound 1 (PAC-1) and Its Cellular Colocalization with Caspase-3,” Journal of Medicinal Chemistry 52, no. 18 (2009): 5721–31. doi:10.1021/jm900722z
   PubMed Web of Science ®Google Scholar
• S. X. Cai, B. Nguyen, S. Jia, J. Herich, J. Guastella, S. Reddy, B. Tseng, J. Drewe, and S. Kasibhatla, “Discovery of Substituted N-Phenyl Nicotinamides as Potent Inducers of Apoptosis Using a Cell- and Caspase-Based High Throughput Screening Assay,” Journal of Medicinal Chemistry 46, no. 12 (2003): 2474–81. doi:10.1021/jm0205200
   PubMed Web of Science ®Google Scholar
• S. Pearce, “The Importance of Heterocyclic Compounds in anti-Cancer Drug Design,” Drug Discovery (2017): 67–70.
   Google Scholar
• M. Ilakiyalakshmi and A. A. Napoleon, “Review on Recent Development of Quinoline for Anticancer Activities,” Arabian Journal of Chemistry 15, no. 11 (2022): 104168. doi:10.1016/j.arabjc.2022.104168
   Web of Science ®Google Scholar
• B. S. Mathada, “The Versatile Quinoline and Its Derivatives as anti-Cancer Agents: An Overview,” Polycyclic Aromatic Compounds 17 (2022): 1–13. doi:10.1080/10406638.2022.2089177
   Google Scholar
• L. Krstulović, M. Leventić, V. Rastija, K. Starčević, M. Jirouš, I. Janić, M. Karnaš, K. Lasić, M. Bajić, and L. Glavaš-Obrovac, “Novel 7-Chloro-4-Aminoquinoline-Benzimidazole Hybrids as Inhibitors of Cancer Cells Growth: Synthesis, Antiproliferative Activity, in Silico ADME Predictions, and Docking,” Molecules 28, no. 2 (2023): 540. doi:10.3390/molecules28020540
   PubMed Web of Science ®Google Scholar
• E. O. Erhirhie, N. E. Ekene, and D. L. Ajaghaku, “Guidelines on Dosage Calculation and Stock Solution Preparation in Experimental Animals Studies,” Journal of Natural Science Research 18, no. 4 (2014): 100–6.
   Google Scholar
• Organisation for Economic Co-operation and Development. Test No. 423: Acute Oral Toxicity-Acute Toxic Class Method (Paris, France: OECD Publishing, 2009). doi:10.1787/80745788
   Google Scholar
• T. Shimada and K. Yamagata, “Pentylenetetrazole-Induced Kindling Mouse Model,” Journal of Visualized Experiments 136 (2018): 1–10. doi:10.3791/56573
   Google Scholar
• N. Siddiqui, M. S. Alam, M. Sahu, M. S. Yar, O. Alam, and M. J. Siddiqui, “Antidepressant, Analgesic Activity and SAR Studies of Substituted Benzimidazoles,” Asian Journal of Pharmaceutical Research 6 (2016): 170–4. doi:10.5958/2231–5691
   Google Scholar
• D. Dhingra and R. Valecha, “Evaluation of the Antidepressant-Like Activity of Aqueous and Ethanolic Extracts of Terminalia bellirica Roxb. Fruits in Mice,” Indian Journal of Experimental Biology 45, no. 7 (2007): 610–6. http://nopr.niscpr.res.in/handle/123456789/5331.
   PubMed Web of Science ®Google Scholar
• A. Monks, D. Scudiero, P. Skehan, R. Shoemaker, K. Paull, D. Vistica, C. Hose, J. Langley, P. Cronise, A. Vaigro-Wolff, et al, “Feasibility of a High-Flux Anticancer Drug Screen Utilizing a Diverse Panel of Human Tumor Cell Lines in Culture,” Journal of the National Cancer Institute 83, no. 11 (1991): 757–66. doi:10.1093/jnci/83.11.757
   PubMed Web of Science ®Google Scholar
• M. R. Boyd and K. D. Paull, “Some Practical Considerations and Applications of the National Cancer Institute in Vitro Anticancer Drug Discovery Screen,” Drug Development Research 34, no. 2 (1995): 91–109. doi:10.1002/ddr.430340203
   Web of Science ®Google Scholar
• R. H. Shoemaker, “The NCI60 Human Tumour Cell Line Anticancer Drug Screen,” Nature Reviews Cancer 6 (2006): 813–23. doi:10.1038/nrc1951
   PubMed Web of Science ®Google Scholar